As IRAK4 signaling was also thought to be a mechanism of adaptive resistance in the setting of FLT3‐mutant AML,152 a phase I/II trial of Emavusertib, a novel oral dual IRAK4 and FLT3 inhibitor, was undertaken in patients with R/R MDS/AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.